CA3149406A1 - Novel anti-cldn18.2 antibodies - Google Patents

Novel anti-cldn18.2 antibodies Download PDF

Info

Publication number
CA3149406A1
CA3149406A1 CA3149406A CA3149406A CA3149406A1 CA 3149406 A1 CA3149406 A1 CA 3149406A1 CA 3149406 A CA3149406 A CA 3149406A CA 3149406 A CA3149406 A CA 3149406A CA 3149406 A1 CA3149406 A1 CA 3149406A1
Authority
CA
Canada
Prior art keywords
antibodies
novel anti
same
antigen
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3149406A
Other languages
English (en)
French (fr)
Inventor
Xueming Qian
Zhen Li
Fei TENG
Hongjun Li
Hui CHAI
Huanhuan GUO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Transcenta Therapeutics Co Ltd
Transcenta Holding Ltd
Transcenta Therapeutics Inc
Original Assignee
Suzhou Transcenta Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Transcenta Therapeutics Co Ltd filed Critical Suzhou Transcenta Therapeutics Co Ltd
Publication of CA3149406A1 publication Critical patent/CA3149406A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA3149406A 2019-08-20 2020-08-20 Novel anti-cldn18.2 antibodies Pending CA3149406A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019101563 2019-08-20
CNPCT/CN2019/101563 2019-08-20
CNPCT/CN2020/097559 2020-06-22
CN2020097559 2020-06-22
PCT/CN2020/110220 WO2021032157A1 (en) 2019-08-20 2020-08-20 Novel anti-cldn18.2 antibodies

Publications (1)

Publication Number Publication Date
CA3149406A1 true CA3149406A1 (en) 2021-02-25

Family

ID=74659946

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3149406A Pending CA3149406A1 (en) 2019-08-20 2020-08-20 Novel anti-cldn18.2 antibodies

Country Status (11)

Country Link
US (1) US20220306765A1 (https=)
EP (1) EP4017883A4 (https=)
JP (1) JP7767270B2 (https=)
KR (1) KR20220045040A (https=)
CN (1) CN114630840B (https=)
AU (1) AU2020332585A1 (https=)
BR (1) BR112022003147A2 (https=)
CA (1) CA3149406A1 (https=)
MX (1) MX2022002111A (https=)
TW (1) TW202120558A (https=)
WO (1) WO2021032157A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115975032A (zh) * 2022-12-19 2023-04-18 华润生物医药有限公司 一种cldn18.2抗体及其应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210110339A (ko) * 2018-12-28 2021-09-07 난징 진스크립트 바이오테크 컴퍼니 리미티드 클라우딘18.2 결합 모이어티 및 그 용도
SG11202108398YA (en) 2019-02-01 2021-08-30 Novarock Biotherapeutics Ltd Anti-claudin 18 antibodies and methods of use thereof
WO2022098972A1 (en) 2020-11-08 2022-05-12 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
US20240307564A1 (en) * 2021-02-19 2024-09-19 Suzhou Transcenta Therapeutics Co., Ltd. Anti-cldn18.2 antibody conjugates
CN113151211B (zh) * 2021-03-11 2022-06-14 中国科学院合肥物质科学研究院 一种α-1,3-岩藻糖基转移酶突变体及利用该突变体制备3-岩藻糖基乳糖的应用
US12600774B2 (en) * 2021-05-31 2026-04-14 Shijiazhuang Yiling Pharmaceutical Co., Ltd. Monoclonal antibodies against CLDN18.2 and Fc-engineered versions thereof
WO2023025306A1 (zh) * 2021-08-27 2023-03-02 三优生物医药(上海)有限公司 靶向pd-l1和cldn18.2的双特异性抗体及其制备方法和应用
JP2024540062A (ja) * 2021-11-05 2024-10-31 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 抗ｃｌｄｎ１８．２抗体及びその用途
CN116410326A (zh) * 2021-12-30 2023-07-11 三优生物医药(上海)有限公司 抗cd40×cldn18.2双特异性抗体及其用途
WO2023221935A1 (zh) * 2022-05-17 2023-11-23 苏州创胜医药集团有限公司 结合pd-l1和cldn18.2的抗体及其用途
TW202415407A (zh) * 2022-06-30 2024-04-16 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗cldn18.2抗體的藥物製劑
WO2024041574A1 (en) * 2022-08-24 2024-02-29 Suzhou Transcenta Therapeutics Co., Ltd. Non-invasive methods using anti-cldn18.2 antibody-radionuclide conjugates
CN118667003A (zh) * 2023-03-16 2024-09-20 亘喜生物科技（上海）有限公司 特异性结合Claudin18.2的抗体及其制法和应用
CN116903745B (zh) * 2023-09-13 2023-11-14 苏州仁端生物医药科技有限公司 一种抗人Claudin18.2的单克隆抗体及其应用
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
TW202541840A (zh) * 2023-12-19 2025-11-01 大陸商蘇州創勝醫藥集團有限公司 包含抗ｃｌａｕｄｉｎ１８．２抗體的製劑
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
JP6499079B2 (ja) * 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
US10858415B2 (en) * 2014-01-29 2020-12-08 Tron—Translationale Onkologie An Der Universitatsmedizin Der Johannes Guttenberg-Universitat Mainz Gemeinnuizige Gmbh Peptide mimotopes of claudin 18.2 and uses thereof
CN120518772A (zh) 2014-07-17 2025-08-22 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
SG11202007055QA (en) * 2018-03-08 2020-09-29 Phanes Therapeutics Inc Anti-claudin 18.2 antibodies and uses thereof
EP3765522A4 (en) * 2018-03-14 2022-05-18 Beijing Xuanyi Pharmasciences Co., Ltd. ANTI-CLAUDIN 18.2 ANTIBODIES
WO2019242505A1 (zh) * 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115975032A (zh) * 2022-12-19 2023-04-18 华润生物医药有限公司 一种cldn18.2抗体及其应用
CN115975032B (zh) * 2022-12-19 2024-06-07 华润生物医药有限公司 一种cldn18.2抗体及其应用

Also Published As

Publication number Publication date
TW202120558A (zh) 2021-06-01
BR112022003147A2 (pt) 2022-05-17
MX2022002111A (es) 2022-03-17
WO2021032157A1 (en) 2021-02-25
US20220306765A1 (en) 2022-09-29
KR20220045040A (ko) 2022-04-12
EP4017883A1 (en) 2022-06-29
JP7767270B2 (ja) 2025-11-11
CN114630840A (zh) 2022-06-14
AU2020332585A1 (en) 2022-02-17
JP2022545660A (ja) 2022-10-28
CN114630840B (zh) 2024-08-02
EP4017883A4 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
CA3149406A1 (en) Novel anti-cldn18.2 antibodies
MX2022007961A (es) Nuevos anticuerpos anti-fgfr2b.
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.
MX2024007966A (es) Anticuerpos anti-tslp novedosos.
WO2021183839A3 (en) Novel anti-lilrb4 antibodies and derivative products
MX2022007960A (es) Nuevos anticuerpos anti-fgfr2b.
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
WO2020084305A9 (en) Bicyclic peptide ligands and uses thereof
MX2023008423A (es) Anticuerpos anti-gremlin1 novedosos.
WO2020123300A3 (en) Kras variant mrna molecules
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2025009320A (es) Anticuerpos anti-cd19 novedosos
EP3978532A4 (en) NEW CLDN18.2-BINDING MOLECULES
WO2019224718A3 (en) Psma binding agents and uses thereof
EP3872093A4 (en) ANTI-CLDN18.2 ANTIBODIES AND USES THEREOF
ZA202106602B (en) Claudin 6 antibodies and uses thereof
MY207121A (en) Anti-ror antibody constructs
WO2018109170A3 (en) Il-11ra antibodies
WO2018109174A3 (en) Il-11 antibodies
EP4527466A3 (en) Anti-dll3 chimeric antigen receptors and uses thereof
WO2018170351A8 (en) Anti-phf-tau antibodies and uses thereof
WO2017214170A3 (en) Baff-r antibodies and uses thereof
PH12020550078A1 (en) Novel anti-cd3epsilon antibodies
WO2017106684A3 (en) Antibodies specifically binding hla-dr and their uses
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240724

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240724

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240820

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240820

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241109

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241126

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241126

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250414

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250725

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250725

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251217